Biodesix, Inc. (NASDAQ:BDSX) Stock Has Average Target Price of $34.20 According to Brokerages

Biodesix logo with Healthcare background
Image from MarketBeat Media, LLC.

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $34.20.

A number of equities analysts have weighed in on the company. Canaccord Genuity Group boosted their price target on Biodesix from $27.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, August 10th. Weiss Ratings upgraded shares of Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, September 8th. HC Wainwright lowered their target price on Biodesix from $38.00 to $34.00 and set a "buy" rating for the company in a report on Monday, November 9th. TD Cowen reiterated a "buy" rating and set a $40.00 price target (up from $30.00) on shares of Biodesix in a report on Tuesday, October 13th. Finally, Lake Street Capital decreased their target price on shares of Biodesix from $40.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, November 6th.

View Our Latest Stock Analysis on Biodesix

Biodesix Stock Down 8.9%

Shares of NASDAQ BDSX opened at $7.56 on Friday. Biodesix has a 12-month low of $5.26 and a 12-month high of $31.97. The firm's 50-day simple moving average is $22.08 and its 200 day simple moving average is $18.83. The company has a quick ratio of 2.96, a current ratio of 2.96 and a debt-to-equity ratio of 5.43. The company has a market cap of $83.84 million, a price-to-earnings ratio of -2.74 and a beta of 0.65.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.75). Biodesix had a negative net margin of 25.74% and a negative return on equity of 442.34%. The company had revenue of $24.04 million for the quarter, compared to analyst estimates of $27.48 million. On average, research analysts expect that Biodesix will post -2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jack Schuler bought 100,000 shares of the company's stock in a transaction on Tuesday, November 10th. The shares were purchased at an average price of $10.02 per share, with a total value of $1,002,000.00. Following the transaction, the director directly owned 655,810 shares in the company, valued at $6,571,216.20. This represents a 17.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 23.20% of the company's stock.

Institutional Investors Weigh In On Biodesix

Hedge funds and other institutional investors have recently modified their holdings of the stock. AIGH Capital Management LLC purchased a new stake in Biodesix during the second quarter valued at about $15,296,000. Soleus Capital Management L.P. raised its holdings in Biodesix by 14.0% in the 3rd quarter. Soleus Capital Management L.P. now owns 667,835 shares of the company's stock worth $19,922,000 after purchasing an additional 81,877 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Biodesix in the 2nd quarter worth about $1,679,000. Stempoint Capital LP purchased a new stake in shares of Biodesix in the 1st quarter worth about $1,015,000. Finally, Marshall Wace LLP lifted its position in shares of Biodesix by 59.8% in the 3rd quarter. Marshall Wace LLP now owns 185,691 shares of the company's stock worth $5,539,000 after purchasing an additional 69,492 shares during the period. 20.96% of the stock is currently owned by institutional investors.

About Biodesix

(Get Free Report)

Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions. Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies.

Further Reading

Analyst Recommendations for Biodesix (NASDAQ:BDSX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Biodesix Right Now?

Before you consider Biodesix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.

While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines